Review of the Selective Serotonin Reuptake Inhibitors Effects on Precipitating Secondary Osteoporosis and Bone Fractures
Hani Raoul Khouzam
ABSTRACT
The Selective serotonin reuptake inhibitors (SSRIs) are currently being approved for the treatment of several psychiatric conditions. Given the relatively decreased incidence of irreversible adverse effects from this class of psychopharmacological agents, the SSRIs are frequently chosen as first choice intervention by many clinicians. There is an emerging body of studies identifying the subtle and often unrecognized effects of the SSRIs on the development of osteoporosis. These studies suggest a possible correlation between SSRIs and a decrease in bone mineral density and an increased incidence of bone fractures. This review would summarize common causes of primary and secondary osteoporosis with special emphasis on the possible role of SSRIs in precipitating secondary osteoporosis and leading to bone fractures.
